The fact that the kinase activity, as well as cellular localization and nuclear functions of PKM2, can be regulated by small molecule allosteric activators, taken together with the pleotropic biological functions of this enzyme, indicates that PKM2 might be an attractive target not only for tumor therapy, but also when targeting an overactive immune system.136 Recent evidence points to a key role for PKM2 in the pathogenicity of acute kidney injury (AKI).156 Zhou et al. report a novel regulatory mechanism of PKM2 activity, namely S-nitrosylation. The gene discussed is PKM; the disease is neoplasm.